146(top 1%)
papers
13.2K(top 1%)
citations
40(top 1%)
h-index
115(top 1%)
g-index
158
all documents
14.5K
doc citations
2.0K
citing journals

Top Articles

#TitleJournalYearCitations
1Signatures of mutational processes in human cancerNature20138,060
2SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomasNature Genetics2009862
3Subclonal diversification of primary breast cancer revealed by multiregion sequencingNature Medicine2015711
4Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor ResistanceClinical Cancer Research2009297
5Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancerNature Genetics2014254
6Somatic mutations reveal asymmetric cellular dynamics in the early human embryoNature2017229
7Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancerRadiotherapy and Oncology2003170
8Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosisBritish Journal of Cancer2009123
9The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in CaucasiansCancer Cell2011104
10Impaired health-related quality of life after chemoradiotherapy for anal cancer: Late effects in a national cohort of 128 survivorsActa Oncológica2013102
11Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter?Oncologist2008101
12Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy GroupActa Oncológica200594
13Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled studyEuropean Journal of Cancer200692
14Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor statusJournal of Steroid Biochemistry and Molecular Biology200989
15Aromatase inhibition 2013: clinical state of the art and questions that remain to be solvedEndocrine-Related Cancer201388
16Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemiaLeukemia201277
17Aromatase inhibitors in breast cancer.Endocrine-Related Cancer200476
18CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast CancerPLoS ONE200874
19Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancerRadiotherapy and Oncology200467
20Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or PaclitaxelPLoS ONE201165
21An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samplesJournal of Steroid Biochemistry and Molecular Biology200862
22Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumorsBMC Cancer201362
23Patterns of genomic evolution in advanced melanomaNature Communications201862
24Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine ManipulationClinical Cancer Research201158
25Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancerBreast Cancer Research201258
26P53 and its molecular basis to chemoresistance in breast cancerExpert Opinion on Therapeutic Targets201257
27The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuumAnnals of Oncology201156
28Breast cancer prognostication and prediction in the postgenomic eraAnnals of Oncology200755
29Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemiaOncogene201252
30Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?European Journal of Cancer200951
31Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysisActa Oncológica200747
32MicroRNA-15b is induced with E2F-controlled genes in HPV-related cancerBritish Journal of Cancer201146
33Lapatinib in early breast cancer—questions to be resolvedLancet Oncology, The201346
34Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF RegulationJournal of Investigative Dermatology201546
35Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the driversOncogene201344
36Chemoradiotherapy of Anal Carcinoma: Survival and Recurrence in an Unselected National CohortInternational Journal of Radiation Oncology Biology Physics201243
37SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancerEuropean Journal of Cancer201243
38Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancerAnnals of Oncology200641
39Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancerBritish Journal of Cancer201241
40The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapyExpert Opinion on Pharmacotherapy201441
41On the use of margins for geometrical uncertainties around the rectum in radiotherapy planningRadiotherapy and Oncology200440
42Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivorsJournal of Cancer Survivorship200840
43APOBEC3A/B deletion polymorphism and cancer riskCarcinogenesis201839
44MDM2promoter SNP285 and SNP309; phylogeny and impact on cancer riskOncotarget201139
45Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA studyAnnals of Oncology201038
46RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancerAnnals of Oncology201138
47Molecular basis for therapy resistanceMolecular Oncology201037
48Additive endocrine therapy for advanced breast cancer – back to the futureActa Oncológica200936
49Twenty-five years with adjuvant chemotherapy for colon cancer – a continuous evolving conceptActa Oncológica201536
50Testing the new ICRU 62 ‘Planning Organ at Risk Volume’ concept for the rectumRadiotherapy and Oncology200535